Drug discovery of next generation-erythropoiesis stimulating agent
| Project/Area Number |
26860179
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General medical chemistry
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
Kaneko Hiroshi 東北大学, 医学(系)研究科(研究院), 助教 (80635558)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | GATA転写因子 / エリスロポエチン / 創薬 / 遺伝子発現制御 / 低分子化合物 / GATA因子 |
|---|
| Outline of Final Research Achievements |
Erythropoietin (EPO) is a humoral factor potentiating erythropoiesis. EPO expression was strictly regulated by oxygen level in vivo. Recent studies revealed that Epo expression is repressed by GATA transcription factors in a part of epithelial tissues in vivo. In this study, I utilized genetic and pharmacological approach to inhibit the function of GATA factors and elucidated that disturbance of GATA factors resulted in the release of Epo expression from non-canonical EPO producing cells. These evidences clearly demonstrated the validity of GATA factors as novel therapeutic target of renal anemia.
|
Report
(3 results)
Research Products
(3 results)
